NASDAQ · Biotechnology

Calliditas Therapeutics AB (publ) (CALT) Stock

$40.00 -0.10% NASDAQ: CALT Healthcare

Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems.

Valuation

MetricValue
Price$40.00
Market Cap$2.15B
P/E Ratio-22.08
P/B Ratio30.76
P/S Ratio17.07
EPS (TTM)$-17.38
52-Week High$43.00
52-Week Low$15.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-84.68%
ROA-24.53%
ROCE-25.74%
Gross Margin93.62%
Operating Margin-31.85%
Net Margin-38.63%
Debt/Equity2.92
Current Ratio3.13

Annual Financials (USD)

Metric20192020202120222023
Revenue$185.0M$1.0M$229.0M$803.0M$1.2B
Operating Profit$-28.0M$-380.0M$-524.0M$-422.0M$-384.0M
Net Profit$-33.0M$-437.0M$-510.0M$-412.0M$-466.0M
EPS$-1.76$-19.46$-20.04$-15.56$-17.38
Op Margin-15.2%-43446.2%-228.7%-52.5%-31.9%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$845.0M$1.5B$1.5B$2.0B$1.9B
Total Liabilities$57.0M$250.0M$452.0M$1.2B$1.6B
Cash$754.0M$996.0M$956.0M$1.2B$974.0M
Borrowings$6.0M$5.0M$213.0M$729.0M$979.0M

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-71.0M$-309.0M$-462.0M$-311.0M$-435.0M
Investing Cash Flow$-52.0M$-345.0M$-47.0M$-8.0M$-27.0M
Financing Cash Flow$-10.0M$-119.0M$-83.0M$94.0M$-27.0M
Net Cash Flow$97.0M$243.0M$-41.0M$294.0M$-275.0M
Free Cash Flow$-87.0M$-309.0M$-484.0M$-314.0M$-447.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.38
EV / EBITDA-56.04
FCF Yield-2.17%
Quick Ratio3.08
Interest Coverage-5.25
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease. Its flagship investigational product is Setanaxib, a NOX inhibitor. Setanaxib is currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Furthermore, it is being evaluated in Phase 2 studies for various other indications, including squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Calliditas's pipeline also includes Budenofalk 3 mg oral capsules, which are under development for the treatment of autoimmune hepatitis. The company was established in 2004 and has its corporate headquarters located in Stockholm, Sweden.

Calliditas Therapeutics AB (publ) is headquartered in SE.

Calliditas Therapeutics AB (publ) (CALT) stock trades at $40.00 with a market capitalization of $2.15B. The stock is valued at a price-to-earnings (P/E) ratio of -22.08, price-to-book of 30.76, price-to-sales of 17.07. Over the past 52 weeks the stock has ranged between $15.25 and $43.00, and currently trades 7.0% below its 52-week high.

On profitability, Calliditas Therapeutics AB (publ) generates a return on equity (ROE) of -84.68%, return on capital employed of -25.74%, an operating margin of -31.85%, a net profit margin of -38.63%.

Official website: www.calliditas.se

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides